Celgene Corporation reported yesterday that a Phase 3 clinical trial of Revlimid (lenalidomide) in first-line multiple myeloma patients has produced overwhelmingly positive results. The outcome of the trial, known as MM-015, suggests that Revlimid taken in combination with melphalan (Alkeran) and prednisone, followed by continuous Revlimid, produces significant improvement in progression-free survival.

While Revlimid is already prescribed as a front-line drug for multiple myeloma, it is approved for use only in patients for whom other treatments have …

On April 23, the National Institute for Health and Clinical Excellence (NICE) announced its final decision to recommend coverage of Revlimid (lenalidomide) in England and Wales. NICE has endorsed Revlimid in combination with dexamethasone (Decadron) for the treatment of multiple myeloma in patients who have already received prior therapies.

Revlimid is a therapeutic agent that has often proven to be effective in the treatment of relapsed patients. Clinical trials report extended survival times and recession in signs and …